ATHENA, Natural History Study in Alport Syndrome Patients:
Regulus Therapeutics (based in La Jolla, CA, USA) is currently conducting a natural history study for patients with Alport Syndrome, named the ATHENA study. Our goal is to characterize the natural decline of renal function in patients with Alport Syndrome. This study is the first clinical trial in a planned therapeutic development program for patients with Alport Syndrome. Information from this study will be used to support and plan an interventional, Phase 2 proof-of-concept study that should be initiated sometime in 2016.
We are currently enrolling patients at 15 clinical centers in the United States, Canada, France, Germany, Australia and the United Kingdom.
At no cost to them, all patients will be genotyped for Alport-related mutations and will undergo measured GFR assessments every 6 months while on study. Additionally, we understand that not all patients will live in close proximity to one of our clinical centers and we are offering free travel and lodging for all required study visits. Patients may also be given the option of having in-home visits for select study visits.
For more information about the study, including all eligibility criteria and participating clinical centers, please visit: